Skip to main content
OpenTrials
Completed

NCT Number: NCT06997562

Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Greater Occipital Nerve Block Episodic Migraine Sphenopalatine Ganglion Block

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

New Valley University

New Valley, New Valley Governorate, 72511, Egypt

About this study

Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years.
  • Both sexes.
  • Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
  • Failure to achieve adequate relief with at least one prophylactic migraine treatment.

Exclusion criteria

  • Chronic migraine (≥15 headache days per month).
  • History of nerve blocks within the last 6 months.
  • Known allergy to anesthetic agents.
  • Pregnancy or lactation.
  • Active psychiatric conditions affecting compliance.

Treatment and study plan

Greater occipital nerve blockade

Other

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Sphenopalatine ganglion blockade

Other

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Primary outcomes

  1. Degree of headache intensity

    Time frame: 3 months post-procedure

    Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").

Secondary outcomes

  1. Migraine disability assessment score

    Time frame: 3 months post-procedure

    The migraine disability assessment scores are as follows: little or no disability, 5 to 10; moderate disability, 1 to 20; and severe disability, more than 20.

  2. Headache duration

    Time frame: 3 months post-procedure

    Headache duration will be recorded.

  3. Headache frequency

    Time frame: 3 months post-procedure

    Headache frequency will be recorded.

Sponsors and collaborators

Lead sponsor

New Valley University

Other

Registry information

Official study title

Comparative Efficacy of Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 30, 2025
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.